Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of 552-02 Free Base. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 552-02 Free Base SCHEMBL29615808 | 1.00 | SCNN1A (0.67) | SCNN1AKCNH2 | |
| 552-02 Free Base SCHEMBL9913757 | 0.97 | SCNN1A (0.71) | SCNN1A | |
| 552-02 Free Base SCHEMBL2015162 | 0.97 | SCNN1A (0.71) | SCNN1A | |
| 552-02 Free Base SCHEMBL9913774 | 0.97 | SCNN1A (0.71) | SCNN1A | |
| 552-02 Free Base SCHEMBL19348088 | 0.96 | SCNN1A (0.70) | SCNN1A | |
| SCHEMBL916347 | 0.94 | SCNN1A (0.67) | SCNN1A | |
| SCHEMBL14268270 | 0.91 | SCNN1A (0.60) | SCNN1AKCNH2 | |
| SCHEMBL10028716 | 0.91 | SCNN1A (0.60) | SCNN1AKCNH2 | |
| SCHEMBL14268271 | 0.91 | SCNN1A (0.60) | SCNN1AKCNH2 | |
| SCHEMBL10110701 | 0.90 | SCNN1A (0.62) | SCNN1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 184 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250332151-A1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | VERTEX PHARMA (US) | 2025-10-30 | — | — | US | claimed |
| CN-119947720-A | Methods of treating cystic fibrosis | 弗特克斯药品有限公司 | 2025-05-06 | — | — | CN | claimed |
| EP-4525858-A1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | Vertex Pharmaceuticals Incorporated (US) | 2025-03-26 | — | — | EP | claimed |
| WO-2023224931-A1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-11-23 | — | — | WO | claimed |
| EP-4247817-A1 | MACROCYCLES CONTAINING A 1,3,4-OXADIAZOLE RING FOR USE AS MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2023-09-27 | — | — | EP | claimed |
| CN-116670140-A | Macrocyclic compounds containing 1,3, 4-oxadiazole rings as modulators of cystic fibrosis transmembrane conductance regulator | 弗特克斯药品有限公司 | 2023-08-29 | — | — | CN | claimed |
| US-20230099745-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2023-03-30 | — | — | US | claimed |
| WO-2022109573-A1 | MACROCYCLES CONTAINING A 1,3,4-OXADIAZOLE RING FOR USE AS MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-05-27 | — | — | WO | claimed |
| US-12637414-B2 | Arylamides and methods of use thereof | GENZYME CORPORATION (US) | 2026-05-26 | — | — | US | disclosed |
| EP-2819670-B1 | PHARMACEUTICAL COMPOSITION AND ADMINISTRATION THEREOF | VERTEX PHARMA (US) | 2026-05-20 | — | — | EP | disclosed |
| US-12630498-B2 | Arylamides and methods of use thereof | GENZYME CORPORATION (US) | 2026-05-19 | — | — | US | disclosed |
| US-12630521-B2 | Arylamides and methods of use thereof | GENZYME CORPORATION (US) | 2026-05-19 | — | — | US | disclosed |
| US-12624051-B2 | Macrocyclic compounds, compositions, and methods of using thereof | GENZYME CORPORATION (US) | 2026-05-12 | — | — | US | disclosed |
| US-12583824-B2 | 6-membered heteroarylaminosulfonamides for treating diseases and conditions mediated by deficient CFTR activity | GENZYME CORPORATION (US) | 2026-03-24 | — | — | US | disclosed |
| US-20140170244-A1 | 3,5-DIAMINO-6-CHLORO-N-(N-(4-PHENYLBUTYL)CARBAMIMIDOYL) PYRAZINE-2- CARBOXAMIDE COMPOUNDS | PARION SCIENCES, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140107133-A1 | 3,5-DIAMINO-6-CHLORO-N-(N-(4-(4-(2-(HEXYL(2,3,4,5,6-PENTAHYDROXYHEXYL)AMINO)ETHOXY)PHENYL)BUTYL)CARBAMIMIDOYL)PYRAZINE-2-CARBOXAMIDE | PARION SCIENCES, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-8669262-B2 | 3,5-diamino-6-chloro-N-(N-(4-(4-(2-(hexyl(2,3,4,5,6-pentahydroxyhexyl)amino)ethoxy)phenyl)butyl)carbamimidoyl)pyrazine-2-carboxamide | PARION SCIENCES, INC. (US) | 2014-03-11 | — | — | US | disclosed |
| WO-2013181232-A2 | DENDRIMER LIKE AMINO AMIDES POSSESSING SODIUM CHANNEL BLOCKER ACTIVITY FOR THE TREATMENT OF DRY EYE AND OTHER MUCOSAL DISEASES | JOHNSON MICHAEL ROSS (US) | 2013-12-05 | — | — | WO | disclosed |
| US-20130324559-A1 | DENDRIMER LIKE AMINO AMIDES POSSESSING SODIUM CHANNEL BLOCKER ACTIVITY FOR THE TREATMENT OF DRY EYE AND OTHER MUCOSAL DISEASES | PARION SCIENCES, INC. (US) | 2013-12-05 | — | — | US | disclosed |
| US-20130178482-A1 | 3,5-DIAMINO-6-CHLORO-N-(N-(4-(4-(2-(HEXYL(2,3,4,5,6-PENTAHYDROXYHEXYL)AMINO)ETHOXY)PHENYL)BUTYL) CARBAMIMIDOYL)PYRAZINE-2-CARBOXAMIDE | PARION SCIENCES, INC. (US) | 2013-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12637414-B2 | Arylamides and methods of use thereof | CFTR, CLIC1, ABCC1 | SCNN1A 16/4885KCNH2 60/4885 |
| US-20140170244-A1 | 3,5-DIAMINO-6-CHLORO-N-(N-(4-PHENYLBUTYL)CARBAMIMIDOYL) PYRAZINE-2- CARBOXAMIDE COMPOUNDS | CFTR, SCNN1B, SCN5A | SCNN1A 4/4885KCNH2 18/4885 |
| US-12624051-B2 | Macrocyclic compounds, compositions, and methods of using thereof | CFTR, ABCC3, ABCD3 | SCNN1A 86/4885KCNH2 234/4885 |
| US-20140107133-A1 | 3,5-DIAMINO-6-CHLORO-N-(N-(4-(4-(2-(HEXYL(2,3,4,5,6-PENTAHYDROXYHEXYL)AMINO)ETHOXY)PHENYL)BUTYL)CARBAMIMIDOYL)PYRAZINE-2-CARBOXAMIDE | CFTR, ELANE, IL5 | SCNN1A 314/4885KCNH2 901/4885 |
| US-12583824-B2 | 6-membered heteroarylaminosulfonamides for treating diseases and conditions mediated by deficient CFTR activity | CFTR, CLIC1, NHERF1 | SCNN1A 18/4885KCNH2 134/4885 |
| US-20250332151-A1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | CFTR, SLC26A4, SLC26A3 | SCNN1A 12/4885KCNH2 482/4885 |
| US-12630521-B2 | Arylamides and methods of use thereof | CFTR, CLIC1, CLCN2 | SCNN1A 12/4885KCNH2 67/4885 |
| US-20130178482-A1 | 3,5-DIAMINO-6-CHLORO-N-(N-(4-(4-(2-(HEXYL(2,3,4,5,6-PENTAHYDROXYHEXYL)AMINO)ETHOXY)PHENYL)BUTYL) CARBAMIMIDOYL)PYRAZINE-2-CARBOXAMIDE | CFTR, ELANE, IL5 | SCNN1A 314/4885KCNH2 901/4885 |
| US-12630498-B2 | Arylamides and methods of use thereof | CFTR, CLIC1, CLCN2 | SCNN1A 14/4885KCNH2 48/4885 |
| US-20130324559-A1 | DENDRIMER LIKE AMINO AMIDES POSSESSING SODIUM CHANNEL BLOCKER ACTIVITY FOR THE TREATMENT OF DRY EYE AND OTHER MUCOSAL DISEASES | SCNN1B, SCNN1A, SCNN1G | SCNN1A 2/4885KCNH2 60/4885 |
| US-20230099745-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | SCNN1A 5/4885KCNH2 1054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.